A study in the Swedish Malmo Preventive Medicine Program (MPMP) found that men with low testosterone were more likely to develop rheumatoid arthritis. The study participants included 33,000 people born between 1921 and 1949. As part of the study, the participants underwent a number of tests, filled out questionnaires, and provided blood samples.
In the study, low testosterone levels are observed in both men and women with rheumatoid arthritis (RA). Further study is required to determine whether low testosterone levels are to blame for the onset of RA, or it is RA that drops the levels of testosterone. Continue reading →
Arthritis Consumer Experts (ACE) is asking for your valuable feedback on new BC PharmaCare policy.
Arthritis Consumer Experts (ACE) is asking for your valuable feedback on new BC PharmaCare policy. Gathering your views is very important to the advocacy work that we do on your behalf.
This survey includes 13 questions for people living with arthritis and will take approximately 10 minutes to complete. Your participation will be anonymous and the results will be pooled for analysis to assure your complete privacy. Your responses will in no way impact on your health care or public health insurance coverage.
Thank you for taking the time to participate in this important survey. Your feedback helps us to improve the quality and relevance of Arthritis Consumer Experts’ work.
A team of researchers has developed Canada’s first set of systematic measures for tracking how well or poorly health systems are doing in providing services to people who have inflammatory arthritis (IA), a potentially crippling disease that is on the rise in Canada.
The researchers developed six key measures for gauging access to specialist care and initiation of treatment for people with IA, a disease grouping that includes rheumatoid arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, and psoriatic arthritis. The work is described in March issue of The Journal of Rheumatology.
People who receive early diagnosis and start of treatment have a better chance of responding well and avoiding permanent joint damage from rheumatoid arthritis (RA), the most common form of IA. There is a growing body of evidence that early detection and treatment are also crucial to good outcomes for people who have other types of IA. Continue reading →
Arthritis in Saskatchewan – Surveying Saskatchewan electoral candidates
Do you have a burning question you would like to ask?
Arthritis Consumer Experts (ACE) asks Saskatchewan’s political leaders to share their plan on how to improve arthritis prevention, treatment and care.
Arthritis has devastating and debilitating effects on the lives of more than 150,000 Saskatchewan residents aged 15 years and above. Arthritis is the leading cause of disability and work disability in Saskatchewan. About a quarter of the population with arthritis between 20 and 54 years of age in Saskatchewan were not in the labour force because of their arthritis, costing Saskatchewan’s economy more than $640 million in productivity losses.
…oppose changes to planned expansion to BC government’s Reference Drug Plan. Better Pharmacare Coalition eager to work with government to get it right for patients
A recent Better Pharmacare Coalition (BPC) poll has found that British Columbians oppose expansion of the Ministry of Health’s Reference Drug Program based on concerns that expansion could compromise patient health.
The BC government has approved amendments to the Drug Price Regulation that will expand the Ministry of Health’s Reference Drug Program (RDP). In anticipation of this expansion, the BPC conducted an online poll, which found a resounding 82% of British Columbians are concerned that administrators of the BC PharmaCare program will be implementing a policy that tells physicians which medications they can prescribe for patients, even if it goes against physicians’ opinions of the best care for their patients. Continue reading →